BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Padilla-Quirarte HO, Lopez-Guerrero DV, Gutierrez-Xicotencatl L, Esquivel-Guadarrama F. Protective Antibodies Against Influenza Proteins. Front Immunol 2019;10:1677. [PMID: 31379866 DOI: 10.3389/fimmu.2019.01677] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Wittwer K, Zimmer G, Rommel M, Krebs Y, Rezinciuc S, Sawatsky B, Pfaller CK. Non-neutralizing antibody responses to vesicular stomatitis virus-vectored influenza A virus vaccines correlate with protection.. [DOI: 10.1101/2022.11.02.514911] [Reference Citation Analysis]
2 Rahman S, Hasan M, Alam MS, Uddin KMM, Moni S, Rahman M. The evolutionary footprint of influenza A subtype H3N2 strains in Bangladesh: implication of vaccine strain selection. Sci Rep 2022;12:16186. [PMID: 36171388 DOI: 10.1038/s41598-022-20179-7] [Reference Citation Analysis]
3 Graaf A, Petric PP, Sehl-Ewert J, Henritzi D, Breithaupt A, King J, Pohlmann A, Deutskens F, Beer M, Schwemmle M, Harder T. Cold-passaged isolates and bat-swine influenza a chimeric viruses as modified live-attenuated vaccines against influenza a viruses in pigs. Vaccine 2022:S0264-410X(22)01108-2. [PMID: 36137904 DOI: 10.1016/j.vaccine.2022.09.013] [Reference Citation Analysis]
4 Rioux ML, Ge A, Yourkowski A, Francis ME, Mcneil M, Selim A, Xue B, Darbellay J, Kelvin AA. Pre-existing immunity to influenza viruses through infection and/or vaccination leads to viral mutational signatures associated with unique immune responses during a subsequent infection.. [DOI: 10.1101/2022.09.07.507060] [Reference Citation Analysis]
5 Mokhtary P, Pourhashem Z, Mehrizi AA, Sala C, Rappuoli R. Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections. Biomedicines 2022;10:1861. [DOI: 10.3390/biomedicines10081861] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Graaf A, Petric PP, Sehl-ewert J, Henritzi D, Breithaupt A, King J, Pohlmann A, Deutskens F, Beer M, Schwemmle M, Harder T. Cold-passaged isolates and bat-swine influenza A chimeric viruses as modified live-attenuated vaccines against influenza A viruses in pigs.. [DOI: 10.1101/2022.06.20.496807] [Reference Citation Analysis]
7 Shahsavandi S, Ebrahimi MM, Fotouhi F, Tebianian M. A Combination of Recombinant HA1-and Nucleoprotein-Based Chitosan Nanoparticles Induces Early and Potent Immune Responses Against the H9N2 Influenza Virus. Viral Immunology. [DOI: 10.1089/vim.2021.0207] [Reference Citation Analysis]
8 Dwipa L, Usman SY, Rakhimullah AB, Mutyara K, Indrati AR, Atik N, Muliasari R, Kartasasmita C. The Immunogenicity and Safety of Influenza Vaccines among Indonesian Older adult. Open Access Maced J Med Sci 2022;10:1332-1339. [DOI: 10.3889/oamjms.2022.9034] [Reference Citation Analysis]
9 Kupke A, Volz A, Dietzel E, Freudenstein A, Schmidt J, Shams-eldin H, Jany S, Sauerhering L, Krähling V, Gellhorn Serra M, Herden C, Eickmann M, Becker S, Sutter G. Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein. Vaccines 2022;10:533. [DOI: 10.3390/vaccines10040533] [Reference Citation Analysis]
10 Cheedarla N, Verkerke HP, Potlapalli S, Mclendon KB, Patel A, Frank F, Damhorst GL, Wu H, O’sick WH, Graciaa D, Hudaib F, Alter DN, Bryksin J, Ortlund EA, Guarner J, Auld S, Shah S, Lam W, Mattoon D, Johnson JM, Wilson DH, Dhodapkar MV, Stowell SR, Neish AS, Roback JD. Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against native-like vaccine and delta variant spike trimers.. [DOI: 10.1101/2022.02.01.22270279] [Reference Citation Analysis]
11 Reed SG, Ager A. Immune Responses to IAV Infection and the Roles of L-Selectin and ADAM17 in Lymphocyte Homing. Pathogens 2022;11:150. [DOI: 10.3390/pathogens11020150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Qiu J, Tian X, Liu Y, Lu T, Wang H, Shi Z, Lu S, Xu D, Qiu T. Univ-flu: A structure-based model of influenza A virus hemagglutinin for universal antigenic prediction. Computational and Structural Biotechnology Journal 2022;20:4656-66. [DOI: 10.1016/j.csbj.2022.08.052] [Reference Citation Analysis]
13 Khalaj-hedayati A, Chua CLL, Smooker P, Lee KW. Universal influenza vaccine technologies and recombinant virosome production. Methods in Microbiology 2022. [DOI: 10.1016/bs.mim.2022.04.001] [Reference Citation Analysis]
14 Morales-Núñez JJ, Muñoz-Valle JF, Torres-Hernández PC, Hernández-Bello J. Overview of Neutralizing Antibodies and Their Potential in COVID-19. Vaccines (Basel) 2021;9:1376. [PMID: 34960121 DOI: 10.3390/vaccines9121376] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
15 Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK. Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections. Clin Transl Immunology 2021;10:e1345. [PMID: 34667600 DOI: 10.1002/cti2.1345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
16 Kaugars K, Dardick J, de Oliveira AP, Weiss KA, Lukose R, Kim J, Leung L, Rajagopalan S, Wolin S, Akabas L, Knipe DM, Bajic G, Jacobs WR Jr. A recombinant herpes virus expressing influenza hemagglutinin confers protection and induces antibody-dependent cellular cytotoxicity. Proc Natl Acad Sci U S A 2021;118:e2110714118. [PMID: 34417304 DOI: 10.1073/pnas.2110714118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Gonzalez KJ, Strauch EM. Decreased vaccine protection of egg-based influenza vaccine in the elderly and nonhemagglutinin-focused immunity. J Clin Invest 2021;131:151732. [PMID: 34338229 DOI: 10.1172/JCI151732] [Reference Citation Analysis]
18 Schoeman D, Fielding BC. Human Coronaviruses: Counteracting the Damage by Storm. Viruses 2021;13:1457. [PMID: 34452323 DOI: 10.3390/v13081457] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Hermann C, King CG. TB or not to be: what specificities and impact do antibodies have during tuberculosis? Oxford Open Immunology 2021;2:iqab015. [DOI: 10.1093/oxfimm/iqab015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Anthony SM, Van Braeckel-Budimir N, Moioffer SJ, van de Wall S, Shan Q, Vijay R, Sompallae R, Hartwig SM, Jensen IJ, Varga SM, Butler NS, Xue HH, Badovinac VP, Harty JT. Protective function and durability of mouse lymph node-resident memory CD8+ T cells. Elife 2021;10:e68662. [PMID: 34143731 DOI: 10.7554/eLife.68662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Dunagan MM, Hardy K, Takimoto T. Impact of Influenza A Virus Shutoff Proteins on Host Immune Responses. Vaccines (Basel) 2021;9:629. [PMID: 34200539 DOI: 10.3390/vaccines9060629] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Wang J, Shu T, Deng W, Zheng Y, Liao M, Ye X, Han L, He P, Zheng X, Li T, Feng Y, Hu F, Li P, Sun C, Chen L, Li F, Feng L. Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice. J Virol 2021;95:e00059-21. [PMID: 33789991 DOI: 10.1128/JVI.00059-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Tharmalingam T, Han X, Wozniak A, Saward L. Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases. Hum Vaccin Immunother 2021;:1-20. [PMID: 34010089 DOI: 10.1080/21645515.2021.1886560] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
24 Chua KH, Mohamed IN, Mohd Yunus MH, Shafinaz Md Nor N, Kamil K, Ugusman A, Kumar J. The Anti-Viral and Anti-Inflammatory Properties of Edible Bird's Nest in Influenza and Coronavirus Infections: From Pre-Clinical to Potential Clinical Application. Front Pharmacol 2021;12:633292. [PMID: 34025406 DOI: 10.3389/fphar.2021.633292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Stoddard CI, Galloway J, Chu HY, Shipley MM, Sung K, Itell HL, Wolf CR, Logue JK, Magedson A, Garrett ME, Crawford KHD, Laserson U, Matsen FA 4th, Overbaugh J. Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs. Cell Rep 2021;35:109164. [PMID: 33991511 DOI: 10.1016/j.celrep.2021.109164] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 24.0] [Reference Citation Analysis]
26 Dong C, Wang Y, Gonzalez GX, Ma Y, Song Y, Wang S, Kang SM, Compans RW, Wang BZ. Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains. Proc Natl Acad Sci U S A 2021;118:e2024998118. [PMID: 33941704 DOI: 10.1073/pnas.2024998118] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 19.0] [Reference Citation Analysis]
27 Gergen J, Petsch B. mRNA-Based Vaccines and Mode of Action. Curr Top Microbiol Immunol 2021. [PMID: 33591423 DOI: 10.1007/82_2020_230] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Mtambo SE, Amoako DG, Somboro AM, Agoni C, Lawal MM, Gumede NS, Khan RB, Kumalo HM. Influenza Viruses: Harnessing the Crucial Role of the M2 Ion-Channel and Neuraminidase toward Inhibitor Design. Molecules 2021;26:880. [PMID: 33562349 DOI: 10.3390/molecules26040880] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
29 Kerstetter LJ, Buckley S, Bliss CM, Coughlan L. Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses. Front Immunol 2020;11:607333. [PMID: 33633727 DOI: 10.3389/fimmu.2020.607333] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
30 Harshbarger WD, Deming D, Lockbaum GJ, Attatippaholkun N, Kamkaew M, Hou S, Somasundaran M, Wang JP, Finberg RW, Zhu QK, Schiffer CA, Marasco WA. Unique structural solution from a VH3-30 antibody targeting the hemagglutinin stem of influenza A viruses. Nat Commun 2021;12:559. [PMID: 33495478 DOI: 10.1038/s41467-020-20879-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
31 Bray RA, Lee JH, Brescia P, Kumar D, Nong T, Shih R, Woodle ES, Maltzman JS, Gebel HM. Development and Validation of a Multiplex, Bead-based Assay to Detect Antibodies Directed Against SARS-CoV-2 Proteins. Transplantation 2021;105:79-89. [PMID: 33273320 DOI: 10.1097/TP.0000000000003524] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 32.0] [Reference Citation Analysis]
32 Kakkola L, Ikonen N, Julkunen I. Influenza A Viruses (Orthomyxoviridae). Encyclopedia of Virology 2021. [DOI: 10.1016/b978-0-12-814515-9.00046-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Sachak-Patwa R, Byrne HM, Thompson RN. Accounting for cross-immunity can improve forecast accuracy during influenza epidemics. Epidemics 2021;34:100432. [PMID: 33360870 DOI: 10.1016/j.epidem.2020.100432] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Shultz PK, Crofts KF, Holbrook BC, Alexander-Miller MA. Neuraminidase-specific antibody responses are generated in naive and vaccinated newborn nonhuman primates following virus infection. JCI Insight 2020;5:141655. [PMID: 33264104 DOI: 10.1172/jci.insight.141655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Wieczorek K, Szutkowska B, Kierzek E. Anti-Influenza Strategies Based on Nanoparticle Applications. Pathogens 2020;9:E1020. [PMID: 33287259 DOI: 10.3390/pathogens9121020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
36 Islam MSB, Miah M, Hossain ME, Kibria KMK. A conserved multi-epitope-based vaccine designed by targeting hemagglutinin protein of highly pathogenic avian H5 influenza viruses. 3 Biotech 2020;10:546. [PMID: 33251084 DOI: 10.1007/s13205-020-02544-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
37 Bhatta TR, Ryt-Hansen P, Nielsen JP, Larsen LE, Larsen I, Chamings A, Goecke NB, Alexandersen S. Infection Dynamics of Swine Influenza Virus in a Danish Pig Herd Reveals Recurrent Infections with Different Variants of the H1N2 Swine Influenza A Virus Subtype. Viruses 2020;12:E1013. [PMID: 32927910 DOI: 10.3390/v12091013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
38 Bray RA, Lee J, Brescia P, Kumar D, Nong T, Shih R, Woodle ES, Maltzman JS, Gebel HM. Development and validation of a multiplex bead based assay for the detection of antibodies directed against SARS-CoV-2 proteins.. [DOI: 10.1101/2020.09.02.20185199] [Reference Citation Analysis]
39 Marinaik CB, Kingstad-Bakke B, Lee W, Hatta M, Sonsalla M, Larsen A, Neldner B, Gasper DJ, Kedl RM, Kawaoka Y, Suresh M. Programming Multifaceted Pulmonary T Cell Immunity by Combination Adjuvants. Cell Rep Med 2020;1:100095. [PMID: 32984856 DOI: 10.1016/j.xcrm.2020.100095] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
40 Kinsley R, Pronost S, De Bock M, Temperton N, Daly JM, Paillot R, Scott S. Evaluation of a Pseudotyped Virus Neutralisation Test for the Measurement of Equine Influenza Virus-Neutralising Antibody Responses Induced by Vaccination and Infection. Vaccines (Basel) 2020;8:E466. [PMID: 32825702 DOI: 10.3390/vaccines8030466] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Ahmed-Hassan H, Sisson B, Shukla RK, Wijewantha Y, Funderburg NT, Li Z, Hayes D Jr, Demberg T, Liyanage NPM. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections. Front Immunol 2020;11:1979. [PMID: 32973803 DOI: 10.3389/fimmu.2020.01979] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
42 Jang YH, Seong BL. Call for a paradigm shift in the design of universal influenza vaccines by harnessing multiple correlates of protection. Expert Opin Drug Discov 2020;15:1441-55. [PMID: 32783765 DOI: 10.1080/17460441.2020.1801629] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
43 Bazhan S, Antonets D, Starostina E, Ilyicheva T, Kaplina O, Marchenko V, Durymanov A, Oreshkova S, Karpenko L. Immunogenicity and Protective Efficacy of Influenza A DNA Vaccines Encoding Artificial Antigens Based on Conservative Hemagglutinin Stem Region and M2 Protein in Mice. Vaccines (Basel) 2020;8:E448. [PMID: 32784907 DOI: 10.3390/vaccines8030448] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
44 Marinaik CB, Kingstad-bakke B, Lee W, Hatta M, Sonsalla M, Larsen A, Neldner B, Gasper DJ, Kedl RM, Kawaoka Y, Suresh M. Programming Multifaceted Pulmonary T-Cell Immunity by Combination Adjuvants.. [DOI: 10.1101/2020.07.10.197459] [Reference Citation Analysis]
45 Zhao L, Yan Y, Dai Q, Li X, Xu K, Zou G, Yang K, Li W, Guo X, Yang J, Li Y, Xia Q, Cao R, Zhong W. Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials. Antimicrob Agents Chemother 2020;64:e00222-20. [PMID: 32312780 DOI: 10.1128/AAC.00222-20] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
46 Li Y, Wang L, Si H, Yu Z, Tian S, Xiang R, Deng X, Liang R, Jiang S, Yu F. Influenza virus glycoprotein-reactive human monoclonal antibodies. Microbes Infect 2020;22:263-71. [PMID: 32569735 DOI: 10.1016/j.micinf.2020.06.003] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Gouma S, Anderson EM, Hensley SE. Challenges of Making Effective Influenza Vaccines. Annu Rev Virol 2020;7:495-512. [PMID: 32392457 DOI: 10.1146/annurev-virology-010320-044746] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
48 Romeli S, Hassan SS, Yap WB. Multi-Epitope Peptide-Based and Vaccinia-Based Universal Influenza Vaccine Candidates Subjected to Clinical Trials. Malays J Med Sci 2020;27:10-20. [PMID: 32788837 DOI: 10.21315/mjms2020.27.2.2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
49 Gao R, Sheng Z, Sreenivasan CC, Wang D, Li F. Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function. Viruses 2020;12:E276. [PMID: 32121563 DOI: 10.3390/v12030276] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
50 Misra RS, Nayak JL. The Importance of Vaccinating Children and Pregnant Women against Influenza Virus Infection. Pathogens 2019;8:E265. [PMID: 31779153 DOI: 10.3390/pathogens8040265] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
51 Alharbi NK, Qasim I, Almasoud A, Aljami HA, Alenazi MW, Alhafufi A, Aldibasi OS, Hashem AM, Kasem S, Albrahim R, Aldubaib M, Almansour A, Temperton NJ, Kupke A, Becker S, Abu-Obaidah A, Alkarar A, Yoon IK, Azhar E, Lambe T, Bayoumi F, Aldowerij A, Ibrahim OH, Gilbert SC, Balkhy HH. Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels. Sci Rep 2019;9:16292. [PMID: 31705137 DOI: 10.1038/s41598-019-52730-4] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 19.3] [Reference Citation Analysis]
52 Knowlden ZAG, Richards KA, Moritzky SA, Sant AJ. Peptide Epitope Hot Spots of CD4 T Cell Recognition Within Influenza Hemagglutinin During the Primary Response to Infection. Pathogens 2019;8:E220. [PMID: 31694141 DOI: 10.3390/pathogens8040220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]